Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
about
Novel technologies and emerging biomarkers for personalized cancer immunotherapyImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisEvaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma modelsManagement of uveal melanoma: a consensus-based provincial clinical practice guidelineClinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare diseaseCost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanomaPatterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.Ipilimumab in the treatment of metastatic melanoma: management of adverse events.Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Therapeutic use of anti-CTLA-4 antibodies.Ipilimumab in melanoma.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesProportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Pembrolizumab-Induced Pancytopenia: A Case ReportHarnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.Q56898598
P2860
Q26770780-D6513065-81F3-465B-BF0B-BA4C2055A861Q26785746-C00D45A2-6156-4E63-A686-886796E8360EQ28817211-CF9E4206-5B0A-4EF5-827E-BD6FAA3DAB0BQ30388575-DE3FBF23-8AC8-48B6-9552-53772A4685F5Q33643902-D2696B68-8B45-440D-9DAD-627F0679B967Q33930593-D3F09205-1BD9-4A08-BB21-4E148B57491EQ34162609-7A7B5E82-F06E-4BFA-A570-FCD0CC57FACCQ35688401-5BBF6B92-9DAE-4820-B365-F89BCA8BAF7AQ35798996-F2C83BAF-F134-4EBB-B0C5-486D4F4C1EA4Q35913194-04B68365-A216-4719-885E-1FDF961BCECEQ36001592-060F9E68-0E29-4879-A480-EE34D6BFB094Q36086834-4D944577-2898-4DCE-816B-E6B20C8A16A4Q36173638-5F72856B-41EC-4C41-8D0F-389327A6F4A0Q36194822-AF9C95C6-5FFF-4C8D-A862-459FBF832E60Q36505754-087B725B-CC79-4FF0-A763-D65BF65E9EB7Q37091138-DC2B365B-6448-4C8E-B9F5-A3CF5EF0CCF4Q37222127-A89BD952-400F-459E-87B2-A21CC2509937Q37601293-FC20798B-E72A-45B6-98E1-730746E4B0CEQ37601946-1B2984EC-E1D9-4AF8-B414-9B46A9B21214Q38050835-0CBF47F8-E3FB-475C-AB9D-333525C3E141Q38114116-EDE02E6D-F143-4A2C-9D8F-5467DCAFF38CQ38166382-FC4F1048-8EBC-4303-9CA7-74E9DDE9EEC9Q38231154-1BD0C3E6-13D9-40FF-877D-BABB58641B01Q38893697-7C643BAC-AE93-4AD3-8728-D3A55D16FCB6Q39010566-D9B16B62-818D-44C1-BB95-8C7F1885A059Q40355238-83724EA4-A156-4802-AE0B-C13DF242F829Q40964128-C4845B53-773E-44DE-B2E8-6695E3C4FF02Q41136783-4AB0FE47-55AE-4944-ABA2-1E66435E3CE0Q42380935-C1209EE8-5964-4BFC-8193-8F51F6E061BAQ45349601-CFAE63A8-822F-4A0D-AE45-BB8800656520Q50191687-CDC58014-0A4E-4806-BEAE-D3B72FAED2D7Q55342245-D0D69C87-8340-4B69-83D6-672C7CD852CBQ56898598-0060AB3E-E0EC-4D8E-A4D4-7A0400995E22
P2860
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Ipilimumab experience in heavi ...... ity Hospital of Siena (Italy).
@en
Ipilimumab experience in heavi ...... e University Hospital of Siena
@nl
type
label
Ipilimumab experience in heavi ...... ity Hospital of Siena (Italy).
@en
Ipilimumab experience in heavi ...... e University Hospital of Siena
@nl
prefLabel
Ipilimumab experience in heavi ...... ity Hospital of Siena (Italy).
@en
Ipilimumab experience in heavi ...... e University Hospital of Siena
@nl
P2093
P2860
P50
P1476
Ipilimumab experience in heavi ...... sity Hospital of Siena (Italy)
@en
P2093
Angelo Balestrazzi
Anna Maria Di Giacomo
Chiara Nannicini
Clelia Miracco
Erica Bertocci
Francesco Vigni
Maresa Altomonte
Maurizio Biagioli
Valentina Riversi
P2860
P2888
P304
P356
10.1007/S00262-010-0958-2
P577
2010-12-18T00:00:00Z